Q3 2018 EPS Estimates for Alexion Pharmaceuticals, Inc. Boosted by Analyst (ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Equities research analysts at Piper Jaffray Companies raised their Q3 2018 EPS estimates for shares of Alexion Pharmaceuticals in a note issued to investors on Wednesday, October 17th. Piper Jaffray Companies analyst C. Raymond now forecasts that the biopharmaceutical company will post earnings of $1.57 per share for the quarter, up from their previous estimate of $1.54. Piper Jaffray Companies also issued estimates for Alexion Pharmaceuticals’ FY2018 earnings at $6.45 EPS.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.58. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The company’s revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $1.56 earnings per share.

ALXN has been the subject of several other research reports. ValuEngine upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 24th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $152.00 target price for the company in a research note on Monday, July 16th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. Jefferies Financial Group reiterated a “hold” rating and issued a $123.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. Finally, Credit Suisse Group set a $156.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $160.74.

ALXN opened at $125.89 on Thursday. The stock has a market capitalization of $28.74 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.18 and a beta of 0.79. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.72 and a quick ratio of 2.27. Alexion Pharmaceuticals has a twelve month low of $102.10 and a twelve month high of $142.24.

Large investors have recently modified their holdings of the stock. First Hawaiian Bank purchased a new position in Alexion Pharmaceuticals during the third quarter valued at approximately $102,000. Advisory Services Network LLC grew its stake in Alexion Pharmaceuticals by 145.3% during the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 523 shares in the last quarter. Berson & Corrado Investment Advisors LLC purchased a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $205,000. Financial Gravity Wealth Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $211,000. Finally, Essex Financial Services Inc. purchased a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $232,000. 93.17% of the stock is owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

See Also: What are the Benefits of Index Funds?

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply